Navigation Links
Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
Date:7/21/2008

LA JOLLA, Calif., July 21 /PRNewswire/ -- Zenobia Therapeutics, Inc. (Zenobia) announced today that they have initiated research at their facility in La Jolla, California. Zenobia was founded June 1, 2008, is privately funded and moved into their new laboratory and office facilities on July 1. The Zenobia team are leaders in the areas of high-throughput structural biology and fragment-based lead discovery (FBLD).

Zenobia will focus on limited population diseases that are traditionally not pursued by larger companies. Zenobia combines the early-stage drug discovery method of FBLD with the expertise of biologists and clinicians to find treatments for illnesses such as Parkinson's disease, Huntington's disease and Muscular Dystrophy. "There is a niche for companies that are passionate about applying innovative approaches to diseases that are not being addressed by mainstream drug discovery organizations," says Dr. Vicki Nienaber, President and founder of Zenobia. "Our mission is to find cures for these patients by working with foundations, granting agencies and leading biologists and clinicians." Zenobia will also provide access to their technology through a limited number of collaborations and partnerships.

Vicki Nienaber is well known for her pioneering work in techniques to find potential drug molecules using fragment-based screening and structure-based drug design. Vicki has managed both drug discovery and pre-clinical development programs. She was recently the Chief Scientific Officer at ActiveSight, a division of Rigaku Americas Corporation, where she built a diverse team of protein biochemistry, X-ray crystallography and drug discovery experts. Before that, Dr. Nienaber was the Senior Director of Lead Discovery and Crystallography at SGX Pharmaceuticals, where she oversaw strategic drug discovery and structural biology alliances with Novartis and Eli Lilly and initiated their internal kinase lead discovery project. While at Abbott Laboratori
'/>"/>

SOURCE Zenobia Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Shareholders Approve All Matters Proposed by Cell Therapeutics, Inc. at Special Meeting in Lieu of Annual Meeting of Shareholders
2. Cell Therapeutics, Inc. Repays $11.0 million Balance of 2008 Convertible Debt
3. Cell Therapeutics, Inc. Special Meeting in Lieu of Annual Meeting of Shareholders Scheduled for Thursday, June 19, 2008
4. Cell Therapeutics, Inc. Announces Issuance of 2011 Convertible Senior Notes and Common Stock Warrants to a Single Institutional Investor
5. Anesiva and Transcription Factor Therapeutics, Inc. Announce Licensing Agreement for Development and Commercialization of NF-kappa B Clinical Program
6. Cell Therapeutics, Inc. (CTI) to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference
7. Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI)
8. Cell Therapeutics, Inc. (CTI) to Report 2008 First Quarter and Financial Results on May 8
9. Cell Therapeutics, Inc. Sells $64.5 million Units Consisting of Preferred Stock, New 2014 Convertible Senior Notes and Warrants to a Single Institutional Investor
10. CardioVascular BioTherapeutics, Inc. Funding Wound Healing Trial with R&D Partnership
11. CardioVascular BioTherapeutics, Inc. Announces Update on Timing of Form 10-K Filing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... Angeles, CA (PRWEB) July 22, 2014 ... test solutions with the debut of its fluorescent ... of Clinical Chemistry (AACC) meeting in Chicago, July ... or bench top versions, the HRDR-300 is a ... pending technology to analyze fluorescent lateral flow immunoassays ...
(Date:7/21/2014)... July 21, 2014 Lawrence ... Investment Board (WIB) and Las Positas College (LPC) ... technical education and hands-on training for veterans, officials ... Program at Las Positas is designed to ... for engineering technician careers, and establishes a pipeline ...
(Date:7/21/2014)... PHILADELPHIA , July 21, 2014  Mike ... closing of $1.6 million in Series Seed B ... and chemical sensors for the life science, defense, ... Trimaran Capital Partners led the round and was ... 36 Angels.  Said Patterson , "This round ...
(Date:7/19/2014)... 20, 2014 United States Non-Vascular ... GlobalDatas new report, "United States Non-Vascular Stents Market ... the United States Non-Vascular Stents market. The report ... (in units) and average prices (in US dollars) ... Stents and Metal Biliary Stents (Metal Non-Covered Biliary ...
Breaking Biology Technology:Holomic to Debut HRDR-300 Fluorescent Immunoassay Reader at the AACC 2014 2Engineering Program Established for Veterans 2Engineering Program Established for Veterans 3Global Graphene Manufacturing Leader, Graphene Frontiers, Receives Series Seed B Funding To Assure Production Of The Next Generation Of Biological And Chemical Sensor Technology 2United States Non-Vascular Stents Market Outlook to 2020 | Researchmoz 2United States Non-Vascular Stents Market Outlook to 2020 | Researchmoz 3United States Non-Vascular Stents Market Outlook to 2020 | Researchmoz 4
... Quarter of 2007 -, - Tests Delivered Grew 68 Percent ... - Conference Call ... Genomic Health,Inc. (Nasdaq: GHDX ) today reported financial results and ... to $23.4 million in the first quarter of 2008,compared to $14.1 million ...
... CHAPEL HILL, N.C., May 6 There are a ... successful re-launch. An organization,s,sales force must be involved with ... crucial to any successful re-launch effort,according to a study ... you invigorate a sales force? Half of the companies ...
... ExonHit Therapeutics S.A.,(Alternext: ALEHT), a drug and ... its new SpliceArray(TM) for use in disease,modeling ... pre-clinical,research communities. These SpliceArray(TM) products provide the ... genome commercially,available today. ExonHit,s patented unique approach ...
Cached Biology Technology:Genomic Health Announces First Quarter 2008 Financial Results and Business Progress 2Genomic Health Announces First Quarter 2008 Financial Results and Business Progress 3Genomic Health Announces First Quarter 2008 Financial Results and Business Progress 4Genomic Health Announces First Quarter 2008 Financial Results and Business Progress 5Genomic Health Announces First Quarter 2008 Financial Results and Business Progress 6Genomic Health Announces First Quarter 2008 Financial Results and Business Progress 7Genomic Health Announces First Quarter 2008 Financial Results and Business Progress 8Genomic Health Announces First Quarter 2008 Financial Results and Business Progress 9Invigorated Sales Force Key to a Successful Re-Launch 2ExonHit Launches Rat Genome SpliceArray(TM) Products to Expand High Resolution Gene Expression Profiling for use in Disease Modeling and Toxicogenomics 2ExonHit Launches Rat Genome SpliceArray(TM) Products to Expand High Resolution Gene Expression Profiling for use in Disease Modeling and Toxicogenomics 3
(Date:7/21/2014)... A University of California, San Diego School of Medicine-led ... not recognize the potentially serious health consequences of childhood ... in helping their child reach a healthy weight. , ... of the Academy of Nutrition and Dietetics . , ... and physical activity behaviors," said lead author Kyung Rhee, ...
(Date:7/21/2014)... cheating in science are among the topics to ... experts in Montreal at the three International Union ... to August 1, 2014. Some 2,000 participants from ... 14th International Congress of Bacteriology and Applied Microbiology, ... Microbiology, and the 16th International Congress of Virology. ...
(Date:7/21/2014)... 154 hotspots in areas across Riau province on Sunday, ... again following a decline in rainfall. The number ... than what had been reported one day prior, which ... scattered in six regencies and municipalities, most of which ... related haze it creates could potentially spread via winds ...
Breaking Biology News(10 mins):Parents rank their obese children as 'very healthy' 2Montreal hosts International Union of Microbiology Societies congresses 2
... Howard Hughes Medical Institute investigator Brian J. Druker and ... unknown genetic mutations that can trigger cancerous growth. By ... myeloid leukemia (AML) cells, the researchers have dramatically reduced ... abnormalities that might be vulnerable to specific drug treatments. ...
... shows the need for an international moratorium on bottom-trawling ... life, Conservation International (CI) said. , The U.N. Division ... reviewed measures to protect the vulnerable deep oceans of ... lies beyond the national jurisdictions of any individual nation. ...
... that it allows scientists peering inside cells to ... protein they are studying has been developed and ... Medical Institute's Janelia Farm Research Campus in collaboration ... and Florida State University. , The new technique ...
Cached Biology News:New strategy rapidly identifies cancer targets 2New strategy rapidly identifies cancer targets 3UN review shows need to halt destructive fishing practice 2New light microscope sharpens scientists' focus 2New light microscope sharpens scientists' focus 3New light microscope sharpens scientists' focus 4New light microscope sharpens scientists' focus 5New light microscope sharpens scientists' focus 6
Request Info...
Recombinant Equine TNF-alpha/TNFSF1A, CF...
Recombinant Equine IL-4, CF...
actin from rabbit muscle Cell Biology Cytoskeletal Probes Actin and Actin Probes...
Biology Products: